Results 171 to 180 of about 61,558 (234)

Trends in Treatment and Survival Among Patients with Glioblastoma in the United States from 2000 to 2020. [PDF]

Cancers (Basel)
Chen J, Boldig CM, Wu Q, Cardenas HM, Bernard KN, Darko K, Grogan PT, Sun Y, Macaulay RJ, Fonkem E, Etame AB.   +10 more
europepmc   +1 more source

Human Blood‐Brain Tumor Barrier on a Chip to Investigate Personalized Treatment for Glioblastoma Patients

Small, Volume 22, Issue 49, 1 September 2026.
A microfluidic model of the glioblastoma (GBM) margin was developed to mimic patient‐specific blood‐brain tumor barrier (BBTB) function and drug response. The platform revealed inter‐patient variability in barrier integrity and drug sensitivity, offering a tool for personalized therapy evaluation in GBM.
Minsu Ryoo, Gaeun Lee, Jinwoo Jung, Sujin Cho, Sharon Jeeho Ham, Nayeong Kang, Hyeongjin Ahn, Yu Jin Kim, JeongMin Sim, Jeongman Park, Juwon Kim, Sohyun Hwang, Jihwan Yoo, Youn‐Jung Kang, Jaejoon Lim, Jungho Ahn, Song Ih Ahn   +16 more
wiley   +1 more source

Therapy for aggressive pituitary tumors and carcinomas. [PDF]

Rev Endocr Metab Disord
Ilie MD, Lamback E, Gadelha M, Raverot G.   +3 more
europepmc   +1 more source

Elucidating the Pro‐Tumor Role of LncRNA CROCCP2 in Glioma via the miR‐5584‐5p/HOXD11/Autophagy Pathway

Cancer Science, Volume 117, Issue 9, Page 2443-2460, September 2026.
The lncRNA CROCCP2 upregulates HOXD11 by competitively adsorbing miR‐5584‐5p, thereby promoting glioma cell proliferation, migration, and invasion by inhibiting autophagy. It significantly enhances tumor growth in vivo, suggesting it may be a potential therapeutic target for gliomas.
Feng Wang, Ganni Lei, Yuan Peng, Maoqiao Liu, Tianqi Jiang, Minghui Wang, Zhe Wang, Jun Pu, Jia Liu   +8 more
wiley   +1 more source

A single-center retrospective study evaluating the efficacy of anlotinib plus temozolomide for recurrent glioma based on real-world data. [PDF]

Transl Cancer Res
Huang Y, Wei W, Xu Y, Chen P, Tang X, Zheng Y, Li H, Jin M, Ma P, Lan C, Li F.   +10 more
europepmc   +1 more source

circMAN1A2 as an Isoform‐Resolved Circular RNA Hub in Cancer

Cancer Science, Volume 117, Issue 9, Page 2345-2356, September 2026.
circMAN1A2 as an isoform‐resolved circular RNA hub in cancer. circMAN1A2 is generated by back‐splicing of MAN1A2 pre‐mRNA, with alternative circularization producing multiple isoforms, including the predominant circMAN1A2(2–5). Its mechanistic interfaces include miRNA‐associated regulation, RBP binding/proteostasis control, BSJ‐mediated RNA–RNA pairing,
Hanyu Shang, Hui Wang, Yonghang Xu, Lingyun Geng, Yanqing Wang   +4 more
wiley   +1 more source

An ALKBH3 Inhibitor HUHS199 Suppresses Proliferation of Glioblastoma Cells by Targeting 1‐Methyladenosine on GADD45A mRNA

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
HUHS199, a novel inhibitor of ALKBH3, suppresses glioblastoma cell proliferation, induces G1 cell cycle arrest, and increases RNA m1A levels, with concomitant changes in GADD45A mRNA methylation status, highlighting the pathological relevance of ALKBH3‐mediated RNA demethylation in glioblastoma.
Manami Yamada, Hiroaki Hase, Honoka Kitamura, Toshiya Morie, Shuntaro Aoi, Yuko Ueda, Kaori Kitae, Tatsuhiko Furukawa, Nayuta Higa, Ryosuke Hanaya, Kazutake Tsujikawa   +10 more
wiley   +1 more source

Combined <i>in vitro</i> effects of temozolomide and erucic acid on U87 MG cell viability, oxidative stress, and expression of genes involved in apoptotic signalling. [PDF]

Arh Hig Rada Toksikol
Gecili İ, Genç S, Hacımüftüoğlu A, Güner A, Niğde E, Karabulut K, Yıllar DO, Taghizadehehghalehjoughi A, Hassibelnaby AMA.   +8 more
europepmc   +1 more source

Integrated Multi‐Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
An integrative multi‐omics and radiogenomic framework identifies S100B and ITGB5 as complementary biomarkers of glioblastoma heterogeneity. S100B reflects broad glial–malignant programs, whereas ITGB5 marks focal stromal–vascular, immunoregulatory, and radiomic heterogeneity.
Xuhang Yang, Yusong Zhang, Yutuo Zheng, Jian Lin   +3 more
wiley   +1 more source

Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities. [PDF]

Front Oncol
Kutuk T, Atak E, Harrell M, Raval R, Beyer S, Zhu S, Grecula J, Fekrmandi F, Mahase SS, Dibs K, Trifiletti D, Singh R, Elder JB, Wu K, Giglio P, Blakaj DM, Chakravarti A, Palmer J.   +17 more
europepmc   +1 more source